SEARCH:   Advanced

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Nicot, C. Articles by Franchini, G. Search for Related Content PubMed PubMed Citation Articles by Nicot, C. Articles by Franchini, G. Related Collections Neoplasia Apoptosis Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, Vol. 96 No. 1 (July 1), 2000: pp. 275-281 NEOPLASIA Bcl-XL is up-regulated by HTLV-I and HTLV-II in vitro and in ex vivo ATLL samples Christophe Nicot, Renaud Mahieux, Shigeki Takemoto, and Genoveffa Franchini From the Basic Research Laboratory Division of Basic Sciences, Laboratory of Receptor Biology and Gene Expression, National Cancer Institute, National Institutes of Health, Bethesda, MD.     Abstract Top Abstract Introduction Materials and methods Results Discussion References Human T lymphotropic virus type I (HTLV-I) is the etiological agent of adult T-cell lymphocytic leukemia (ATLL), whereas HTLV-II has not been associated with hematopoietic malignancies. The control of apoptotic pathways has emerged as a critical step in the development of many cancer types. As a result, the underlying mechanism of long-term survival of HTLV-I and HTLV-II was studied in infected T cells in vitro and in ex vivo ATLL samples. Results indicate that HTLV-I- and HTLV-II-infected T cells in vitro express high levels of the antiapoptotic protein Bcl compared with other human leukemic T cell lines or uninfected peripheral blood mononuclear cells. The levels of proapoptotic proteins Bax, BAD, and Bak were not significantly altered. HTLV-I and HTLV-II viral transactivators, Tax1 and Tax2, are known to increase expression of cellular genes. These proteins were tested for increased transcription from the human Bcl2 and Bcl-XL promoters. Whereas no effect was observed on the Bcl2 promoter, both Tax1 and Tax2 increased transcription of the Bcl-XL promoter in T cells, although Tax1 appeared to be more efficient than Tax2. The biological significance of these observations was validated by the finding of an increased expression of Bcl-XL in ex vivo ATLL cells, especially from patients unresponsive to various chemotherapy regimens. Altogether, these data suggest that overexpression of Bcl-XL in vivo may be in part responsible for the resistance of ATLL cells to chemotherapy. In addition, inefficient activation of the Bcl-XL promoter by Tax2 may result in a shorter survival time of HTLV-II-infected cells in vivo and a diminished risk of leukemia development. (Blood. 2000;96:275-281) © 2000 by The American Society of Hematology.     Introduction Top Abstract Introduction Materials and methods Results Discussion References Programmed cell death is a normal physiological process essential to tissue remodeling and is characterized by an active physiological mechanism, apoptosis, that eliminates DNA-damaged, senescent, cancer, or virus-infected cells. A wide variety of human diseases, including cancers and degenerative diseases, appears to be associated with dysregulation of the apoptotic pathways.1-4 Bcl2 and related proteins are part of an expanding family involved in the regulation of the apoptotic signaling.5-7 This family is generally divided into 2 groups: the death antagonists (eg, Bcl2, Bcl-XL, and BAG-1) and the death agonists (eg, Bax, Bak, and BAD). Bcl2 and Bcl-XL are associated mainly with mitochondria membranes, where they exert part of their protective functions by preventing the release of cytochrome C to the cytosol and the subsequent activation of caspases.8 The defined mechanism by which Bcl2 and Bcl-XL exert their antiapoptotic functions remains uncertain. A model, whereby homodimers of death agonists induce apoptosis, while heterodimers or homodimers of death antagonists prevent apoptosis,3,9 has been proposed. Alternatively, both agonist homodimers and heterodimers may be active, and the stoichiometry of heterodimers to homodimers may dictate the fate of a cell.10 Other studies indicated that in some instances, Bcl2, Bcl-XL, and Bax might function independently and without the formation of heterodimers.11-13 To counter host apoptotic responses, many viruses have evolved strategies that interfere with key steps of the apoptotic pathway. Some viruses, such as H saimiri, Epstein-Barr virus (EBV), human herpes virus 8 (HHV8), equine herpes virus (EHV)-2, bovine herpes virus (BHV)-4, avian herpes virus (AHV)-1, and the African swine fever virus, carry a cellular homologue of the antiapoptotic protein Bcl2 within their genome.14 Other strategies include the production of viral inhibitors of caspases (cowpox virus, murine herpes virus (MHV) 68, vaccinia virus, and the African swine fever virus); the secretion of soluble cytokine receptors (myxoma virus and EBV); the inhibition of cellular stress responses (Papillomavirus, Polyomavirus, and adenovirus); and the inhibition of death receptor-mediated apoptosis (H saimiri, HHV-8, EHV-2, and BHV-4).14 HTLV-I-mediated T-cell transformation presumably arises from a multistep oncogenic process in which the virus induces chronic T-cell proliferation resulting in an accumulation of genetic defects and the dysregulated growth of infected cells.15 The viral transactivator Tax plays an essential role during the oncogenic process, and its expression is sufficient to immortalize primary T cells and transform rat fibroblasts in vitro.16,17 Although some aspects of viral transformation remain elusive, the Tax effect on cell cycle regulatory proteins, such as p53, p15INK,4 p16INK,4 p21WAF1, and MAD1,18-22 are the key to the viral-induced growth dysregulation of T cells. In addition, Tax also represses the expression of -polymerase and interferes with the DNA repair machinery, thereby increasing the mutation rate in virus-infected cells.23,24 In contrast, HTLV-II, which also immortalizes and transforms T cells in vitro, although it induces a life-long infection, is not associated with hematopoietic malignancies. The poor prognosis in HTLV-I-induced ATLL is associated with the resistance of neoplastic T cells to the conventional combination of high-dose chemotherapy and radiotherapy. The disease is invariably fatal, and generally, survival from onset of the acute disease does not exceed 6-8 months. Treatment with the antiretroviral agent zidovudine (AZT), interferon- (IFN-), all transretinoic acid (ATRA), or arsenic trioxide appears to prolong the survival of some patients, who ultimately relapse in conjunction with the reemergence of drug-resistant neoplastic cells.25-28 We demonstrate that cells infected in vitro by HTLV-I and the related virus HTLV-II have elevated expression of antiapoptotic proteins Bcl2 and Bcl-XL. Because the expression of the proapoptotic proteins Bax, Bak, and BAD were not significantly increased, the ratio of Bcl2 and Bcl-XL homodimers to heterodimers was increased in HTLV-I-infected T cells. Interestingly, whereas both HTLV-I and HTLV-II Tax transactivated the Bcl-XL promoter in human T cells, HTLV-II Tax had a reduced activity. Importantly, the Bcl-XL expression was also markedly increased in uncultured leukemic cells in 6 of 6 ATLL patients tested, and its up-regulated expression appears to correlate with the severity of the disease. As in the case of other histological types of human cancers, these data support the notion that aberrant expression of Bcl-XL may increase the survival of virus-infected T cells as well as their resistance to apoptotic signals, thereby contributing to HTLV-I-induced leukemogenesis.     Materials and methods Top Abstract Introduction Materials and methods Results Discussion References Cell lines Human leukemic T cell lines (Jurkat and Molt-4), HTLV-I-transformed T cell lines (MT-2, MT-4, C8166, and C91/PL), and HTLV-II-transformed T cell lines (C19 and 344Mo) were cultured in Roswell Park Memorial Institute medium (RPMI 1640) supplemented with 10% heat-inactivated fetal calf serum (FCS) (Life Technologies, Gaithersburg, MD), 2 mmol/L L-glutamine, 100 U/mL penicillin, and 100 µg/mL streptomycin. HTLV-I-immortalized cell lines 1185 and 1996 and HTLV-II-immortalized cell line c96II were cultured in RPMI 1640 supplemented with 20% heat-inactivated FCS, 2 mmol/L L-glutamine, 100 U/mL penicillin, and 100 µg/mL streptomycin in the presence of 50 U/mL interleukin-2 (IL-2) (Boehringer Mannheim, Mannheim, Germany). Two weeks prior to analysis, peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll-Hypaque gradient (Hyclone, San Francisco, CA); washed with phosphate-buffered saline (PBS); activated with 5 µg/mL phytohemagglutinin (PHA) for 48 hours; washed in serum-free medium; and then cultured in RPMI 1640 supplemented with 20% serum and 50 U/mL IL-2. Patient samples Lymphocytes from the peripheral blood of healthy volunteers or ATLL patients were purified by Ficoll-Hypaque gradient, washed in PBS, and lysed in radioimmunoprecipitation assay (RIPA) buffer. All samples were obtained after informed consent was received. Plasmids and transfections Expression vectors for HTLV-I Tax, HTLV-II Tax, and mutants M47 and M22 were previously described.29,30 We used luciferase reporter constructs for the human Bcl2 promoters P1 and P2 (Dr C. Paya, Mayo Foundation, Rochester, MN)31 and reporter constructs for the human Bcl-XL promoter luciferase and control vectors (Dr K.E. Boulukos, Faculté de Nice, France).32 Transient transfections were carried out in Jurkat T cells using the Superfect reagent (Quiagen, Madison, WI) according to the manufacturer's instructions. This was done using 5 × 106 cells, 4 µg reporter construct, 1 µg Tax vectors, and 100 ng CMV-RL (renilla) to control transfection efficiency. After 48 hours, transfected cells were collected by centrifugation, washed with PBS, and lysed in reporter lysis buffer (Promega, Madison, WI) and assay using the Dual Luciferase Assay System (Promega). Luciferase activity, measured with a Bertholdt luminometer (EGNG, Gaithersburg, MD), was normalized for transfection efficiency, and standard deviations were calculated from 3 independent transfections. Immunoblots and antibodies Exponentially growing cells were collected by centrifugation, washed with PBS, and lysed in RIPA buffer containing protease inhibitors and 1 mmol/L sodium orthovanadate. Protein concentration was determined by the Bradford assay (Bio Rad Laboratories, Hercules, CA). Protein (50 µg) was resolved on SDS-polyacrylamide Tris-glycine gels (sodium dodecyl sulfate-polyacrylamide tris[hydroxymethyl] aminomethane-glycine gels) (Novex, Bedford, PA) and transferred onto a PVDF membrane (Millipore, San Diego, CA). Nonspecific sites were blocked for 30 minutes at room temperature in a 5% PBS-milk combination, and a primary antibody was diluted in 1% PBS-milk and incubated overnight at 4°C; BAD was incubated overnight at room temperature. A secondary antibody, horseradish peroxidase conjugate diluted in 1% PBS-milk, was incubated for 2 hours at room temperature. Immunoblots were washed 5 times for 15 minutes with TNE (50 mmol/L Tris [pH 7.5], 2 mmol/L ethylenediamine tetraacetic acid [EDTA], 100 mmol/L sodium chloride [NaCl]) 0.05% Tween. The immunoblots were then developed using the chemiluminescence West-Dura (Pierce, Barcelona, Spain). Comparable loading of protein was confirmed by reprobing the membrane with a specific antibody for the housekeeping gene product -tubulin. Each immunoblot is representative of 2 separate experiments using uninfected PBMCs from 2 different donors as a control. The following products were used in the study (brand names in parentheses): primary antibodies Bcl2 (100), Bcl-XS/L (S-18), Bcl-XL (H-62), Bax (P-19), and Bad (K-17) (Santa Cruz Biotechnology, Santa Cruz, CA); secondary antibodies (Santa Cruz Biotechnology); Bak (Ab-1; Calbiochem Oncogene Research Products); and -tubulin (Ab-1; Boehringer-Mannheim). Membrane stripping was performed by immersion in Tris (pH 8), 1% SDS, and 100 mmol/L NaCl for 30 minutes at 62°C; membranes were then washed extensively with 0.1% TNE-Tween and PBS. Immunoprecipitation Total protein extracts (200 µg) were incubated with 4 µg each of Bax, Bak, and BAD antibodies for 4 hours at 4°C, and depletion was further verified by Western blot analysis. The remaining supernatants were incubated with 4 µg Bcl2 or Bcl-XL for 4 hours at 4°C. Immune complexes were captured by adding 30 µL protein alanine/glycine agarose (A/G agarose) (Life Technologies), which was collected by centrifugation and washed twice with 5 volumes of 0.05% PBS-Tween 20. Immunoprecipitates were resuspended in 1 times the loading buffer, boiled for 5 minutes, and resolved on 12.5% SDS-PAGE (polyacrylamide gel electrophoresis). After this was completed, electrotransfer immunoblots were incubated with antibodies specific for Bcl2 or Bcl-XL. Quantifications were realized by densitometry using the Image Quant software (Molecular Dynamics) from 2 independent experiments. The average values, which were calculated from the total intensity of signals corresponding to the homodimers and heterodimers, were expressed as the ratio of homodimers to heterodimers.     Results Top Abstract Introduction Materials and methods Results Discussion References Increased expression of antiapoptotic Bcl2 and Bcl-XL proteins in HTLV- immortalized and HTLV-transformed T cells in vitro Control of the apoptotic pathways has emerged as a critical step in the development of many cancer types. We have previously shown that (1) replication of HTLV-I in human endothelial cells resulted in an increased expression of Bcl233 and (2) HTLV-I -infected T cells in vitro are resistant to apoptosis-inducing treatments.34 To gain further insight into the cellular components involved in the survival of HTLV-I-infected T cells, the levels of apoptotic and antiapoptotic protein expression were studied in the HTLV-I-transformed cell lines (MT-2, MT-4, C8166, and C91/PL) and in the 2 IL-2-dependent HTLV-I-immortalized cell lines (1185 and 1996). The human leukemic T cell lines, Jurkat and Molt-4, as well as normal PBMCs from 2 uninfected donors, were used for comparison. The levels of the Bcl2 protein expression in normal PBMCs were similar to the levels in most HTLV-I-infected T cell lines (MT-2, C91/PL, 1185, and 1996) except the MT-4, C8166, Jurkat, and Molt-4 T cell lines (Figure 1). Markedly, the Bcl2-related antiapoptotic protein Bcl-XL was expressed at much higher levels in all HTLV-I-infected cell lines as compared with the levels in PBMCs and the Molt-4 and Jurkat cells (Figure 1). View larger version (52K): [in this window] [in a new window]   Fig 1. Expression of the Bcl2 family proteins in HTLV-I-transformed and HTLV-I-immortalized cell lines. Total proteins (50 µg) were resolved on 12.5% SDS-PAGE and transferred onto PVDF membranes and probed with specific antibodies for Bcl2, Bcl-XL, Bax, Bak, and BAD. Comparable protein loading was verified using an antibody specific for the housekeeping gene product -tubulin. Results are representative of 2 independent immunoblots using uninfected PBMCs from 2 separate donors. The alternatively spliced proapoptotic Bcl-XS protein was not detected by Western blot, even when an antibody that recognizes both forms of Bcl-X was used (data not shown). Despite a previous report proposing that Tax transrepresses a Bax promoter reporter construct in a transient transfection assay,35 Bax protein expression was not affected in HTLV-I-infected cell lines and was comparable to the expression in PBMCs and Molt-4 cells (Figure 1). This finding is consistent with a recent study that showed no effect of Tax on the endogenous Bax promoter in mouse T cells expressing Tax.36 The absence of Bax expression in the Jurkat cell line has previously been attributed to the presence of a termination codon mutation.37 The expression of proapoptotic Bak was similar in all the cell lines investigated, although there were reduced levels in the Jurkat T cell line. The proapoptotic BAD protein was expressed at similar levels in the MT-2, MT-4, C91/PL, Jurkat, and Molt-4 cell lines, and lower levels were present in the C8166, 1185, and 1996 cell lines and in PBMCs. A comparable loading of protein was confirmed using a specific antibody for the housekeeping gene product -tubulin (Figure 1). A similar analysis used the HTLV-II-transformed 344Mo and C19 cell lines and the HTLV-II-immortalized IL-2-dependent c96II cell line. This study revealed that both the antiapoptotic Bcl2 and Bcl-XL proteins were expressed at higher levels in HTLV-II-infected cell lines than in PBMCs and Jurkat and Molt-4 cell lines (Figure 2). Similar to HTLV-I-infected cells, the levels of the proapoptotic gene product Bax were not increased in HTLV-II-infected cells, and the expressions of Bak and BAD were lower in C19 and c-96II, respectively. Comparable loading of protein was confirmed using a specific antibody for the housekeeping gene product -tubulin (Figure 1). Together these results indicate that both HTLV-I- and HTLV-II-infected cells in vitro have acquired altered cellular signaling pathways that result in high levels of expression of antiapoptotic proteins, mainly Bcl-XL. View larger version (38K): [in this window] [in a new window]   Fig 2. Expression of the Bcl2 family proteins in HTLV-II-transformed and HTLV-II-immortalized cell lines. Total proteins (50 µg) were resolved on 12.5% SDS-PAGE and transferred onto PVDF membranes and probed with specific antibodies for Bcl2, Bcl-XL, Bax, Bak, and BAD. Comparable protein loading was verified using an antibody specific for the housekeeping gene product -tubulin. Results are representative of 2 independent experiments using uninfected PBMCs from 2 separate donors. Tax1 and Tax2 differential transactivation of the human Bcl-XL promoter in Jurkat T cells Tax1 and Tax2, the virus-encoded transactivator Tax proteins of HTLV-I and HTLV-II, respectively, stimulate transcription through distinct cellular pathways including CREB/ATF; NF-B, and serum responsive factor (SRF). To investigate their potential effect, Tax1 and Tax2 were transiently transfected together with human Bcl2 and Bcl-XL promoter reporter constructs in Jurkat T cells. In agreement with a previous report,32 Tax1 was unable to stimulate transcription from either one of the Bcl2 promoters, the P1 Bcl2-Luc or P2 Bcl2-Luc reporter constructs; similarly Tax2 had no significant effect (Figure 3A). Tax1 increased transcription from Bcl-XL promoter more than 4-fold. Although Tax2 had a reduced activity compared to Tax1, it still activated the Bcl-XL promoter approximately 2-fold (Figure 3B). View larger version (16K): [in this window] [in a new window]   Fig 3. Tax transactivates the Bcl-XL promoter through the NF-B pathway in T cells. Jurkat cells were transfected with HTLV-I Tax (Tax1), HTLV-II Tax (Tax2), M22, M47, or pCMV4 vector and (A) P1 Bcl2, (B) P2 Bcl2, (C) Pr Bcl-XL, (D) HTLV-LTR, or (E) NF-B luciferase reporter constructs. Results are representative of 3 independent transfections. The NF-B pathway has previously been shown to stimulate the Bcl-XL promoter.38 As a result, 2 additional Tax mutants that retain the ability to activate the CREB/ATF (M22) or NF-B pathway (M47) were tested. Whereas the M47 mutant increased the Bcl-XL promoter reporter activity, no significant activation was observed with the M22 mutant (Figure 3C). Consistent with these observations, Tax2, which is partially defective in transactivation of Bcl-XL, had a reduced ability to transactivate an NF-B reporter construct in Jurkat T cells. This occurred even though both Tax1 and Tax2 transactivated the HTLV-LTR (long terminal repeat sequence) to a similar extent (Figure 3D). These observations underscore the importance of Tax activation of the NF-B pathway in T-cell survival and/or transformation. Increased antiapoptotic homodimers in HTLV-I-infected T cell lines The mechanism by which Bcl2 and Bcl-XL exert their antiapoptotic functions is unclear. Part of the Bcl2 and Bcl-XL protective effect may occur through heterodimerization with the proapoptotic proteins Bax, Bak, and BAD.3,9,10,39 Thus, a cell's resistance to apoptotic signals may be modulated by the amount of antiapoptotic homodimers that can potentially antagonize increased amounts of proapoptotic proteins through heterodimerization.40 We therefore investigated the intracellular levels of unbound Bcl2 and Bcl-XL as well as the levels bound to the Bax, Bak, and BAD proteins. Protein lysates from HTLV-I (MT-2 and MT-4) or HTLV-II (C19 and c96II) cell lines and uninfected PBMCs were simultaneously immunoprecipitated with antibodies directed against Bax, Bak, and BAD. The immunocomplexes were captured using protein A/G agarose and analyzed for the presence of Bcl2 or Bcl-XL proteins (bound fractions or heterodimers). Proteins remaining in the supernatant were then immunoprecipitated with either Bcl2 or Bcl-XL in order to evaluate the unbound fractions or homodimers (Figure 4A). The relative ratio of homodimers to heterodimers, as quantified by densitometry, indicated an increased ratio in HTLV-I-transformed cells compared with PBMCs. HTLV-II-infected cells also presented an increase of antiapoptotic homodimers, albeit to a lower extent than when compared with HTLV-I-transformed cells. View larger version (63K): [in this window] [in a new window]   Fig 4. Increased antiapoptotic homodimers to heterodimers in HTLV-I-transformed cells. (A) Protein extracts from uninfected PBMCs, HTLV-I cell lines (MT-2 and MT-4), and HTLV-II cell lines (C19 and C96II) were immunoprecipitated with mixed antibodies against Bax, Bak, and BAD, and the immunocomplexes were probed with either Bcl2 or Bcl-XL (heterodimers). Depletion of Bax, BAD, and Bak was confirmed by Western blot, and the proteins in the depleted fraction were immunoprecipitated with antibodies directed against either Bcl2 or Bcl-XL (homodimers). The relative intensity of each band was calculated by densitometry and is presented as an arbitrary unit. (B) The ratio of heterodimers to homodimers was calculated from 2 independent immunoprecipitations. High levels of Bcl-XL expression in leukemic cells from ATLL patients ATLL cells in vivo are resistant to radiation and chemotherapy treatments.27,28 To assess the relevance of our findings in vitro to the ATLL cells ex vivo, we analyzed the levels of antiapoptotic proteins in uncultured blood cells from ATLL patients. The clinical status of the ATLL patients at the time of sample collection is summarized in Table 1. Western blot analysis of ATLL cell lysates revealed levels of Bcl2 expression in ATLL cells comparable to levels of normal PBMCs, as observed in HTLV-I-infected cells in vitro (Figures 1 and 5). BAD expression was not detected in nonactivated PBMCs and patient ATLL cells (data not shown). Importantly, similar to HTLV-I-infected T cells in vitro, all ATLL patient cells analyzed expressed higher levels of Bcl-XL compared with levels from uninfected PBMCs (Figure 5). The only exception noted was patient No. 3; at the time of collection, this patient had very few cells that displayed a neoplastic phenotype (Table 1).                                View this table: [in this window] [in a new window]   Table 1. Clinical features of ATLL patients at the time of sample collection View larger version (50K): [in this window] [in a new window]   Fig 5. Overexpression of Bcl-XL in uncultured acute T-cell lymphocytes from ATLL patients. Lymphocytes from uninfected donors and ATLL patients were isolated by Ficoll-Hypaque gradient, washed, and lysed in RIPA buffer. Total proteins (50 µg) were separated on 12.5% SDS-PAGE transferred onto PVDF membranes and probed with specific antibodies for Bcl2, Bcl-XL, and Bax. Comparable protein loading in each lane was verified using an antibody specific for the housekeeping gene product -tubulin. Results are representative of 2 independent experiments using 2 separate donors for PBMCs. With the exception of patient No. 5, the overall levels of the proapoptotic Bax protein were not significantly different among ATLL cells and normal PBMCs. Interestingly, the sample from patient No. 5 contained high levels of Bcl-XL. The patient failed all therapies and succumbed to the disease a few days after sample collection. Although Bax is generally considered a proapoptotic protein, high levels may indicate a poor prognosis, as recently evidenced by the finding that an increased Bax expression is associated with the high probability of relapse in childhood ALL.41     Discussion Top Abstract Introduction Materials and methods Results Discussion References Accumulating evidence indicates that dysregulation of the physiological cell death suicide program, apoptosis, often leads to uncontrolled accumulation of cells that carry genetic defects. Thus, alteration in apoptotic pathways is frequently associated with the development of cancers and autoimmune and neurodegenerative diseases.1-4 Indeed, overexpression of either Bcl2 or Bcl-XL is found in roughly half of all human cancers, and it is associated with both an increased mutation rate and a resistance of tumor cells to radiotherapy and chemotherapy.33-35 Overexpression of the Bcl-XL protein found in ATLL may explain this malignancy's resistance to chemotherapy. A previous investigation of HTLV-I-infected T-cell resistance to damaging agents in vitro revealed an alteration in cell cycle regulatory proteins.22,34 However, there has not been a thorough study of the Bcl2 protein family in HTLV-I- and HTLV-II-infected T cell lines in vitro and in ex vivo ATLL. In this study we investigated the expression level of some of the Bcl2 family members in various HTLV-I and HTLV-II cell lines as well as in uncultured leukemic cells isolated from ATLL patients. Here we demonstrate that the levels of Bcl2 protein are constitutively higher in most HTLV-I and HTLV-II T cell lines in vitro when compared with noninfected leukemic cells such as Jurkat or Molt-4. However, there were no significant differences observed between cultured PBMCs and HTLV-infected cells in vitro or uncultured PBMCs and ex vivo ATLL cells. Notably, all HTLV-I and HTLV-II cell lines investigated in this study had elevated expression of the antiapoptotic protein Bcl-XL when compared with leukemic T cell lines Jurkat and Molt-4 or with uninfected PBMCs from different donors. In our study, the expressions of proapoptotic Bax, BAD, and Bak proteins were not significantly affected. In addition, the ratio of antiapoptotic Bcl2 and Bcl-XL homodimers to heterodimers was increased in HTLV-I-infected cells compared with the ratio in uninfected PBMCs. Our results also suggest that elevated Bcl-XL expression may preferentially sequester the death agonists and thereby increase the formation of Bcl2 homodimers. Interestingly, HTLV-II-infected cells presented a lower increase of antiapoptotic homodimers compared with HTLV-I-transformed cells. We observed that in vitro Tax, through the NF-B pathway, up-regulates Bcl-XL. This finding parallels the in vivo finding that in ATLL, the NF-B pathway is constitutively activated despite the low level of Tax expression in these cells.42,43 NF-B activation may be the key to increasing the survival of HTLV-I-infected T cells in vitro and in vivo. In support of this theory is the observation that in Tax transgenic mice, treatment with NF-B antisense oligonucleotides is associated with massive apoptotic cell death.44 In addition antisense inhibition of NF-B p65 has been shown to block tumorigenicity and cause tumor regression. Therefore NF-B-induced expression of Bcl-XL may contribute to HTLV-I leukemogenesis. Indeed, increasing evidence indicates that up-regulation of Bcl-XL is a critical step for tumor progression in many cancers such as breast and colorectal cancer, multiple myelomas, ovarian carcinomas, gastric adenomas, non-Hodgkin lymphomas, and Hodgkin disease.46-51 The IL-2/IL-2R pathway is constitutively activated in most HTLV-I-transformed cells in vitro as well as in most ATLL cells in vivo.52,53 However, ATLL cells in vivo likely need several signals to survive and replicate. The inability of HTLV-II to activate this pathway,54 coupled with the lower efficiency of Tax2 activation of the Bcl-XL promoter, may affect the survival of HTLV-II-infected T cells in vivo. In most cases, up-regulation of Bcl2 and/or Bcl-XL is not sufficient for tumor expansion in vivo, and leukemia may result when Bcl2 and/or Bcl-XL cooperate with other oncogenes, such as c-Myc or Ras.55,56 Interestingly, HTLV-I Tax has been shown to increase expression of c-Myc,57 which correlates with an increased neoplastic potential of HTLV-I Tax in transgenic mice.58 In addition, it has also been demonstrated that HTLV-I Tax cooperates with Ras in fibroblast transformation in vitro.59,60 Further studies are needed to determine whether HTLV-II Tax is also able to increase expression and/or cooperate with these oncogenes. The finding that ex vivo ATLL cells from HTLV-I-infected patients also have higher levels of Bcl-XL expression than PBMCs from uninfected donors validates the observations made in HTLV-I-infected T cells in vitro. In the case of HTLV-II, however, it is unfeasible to validate in vitro observations because very few HTLV-II-infected cells are present in the blood of HTLV-II-infected individuals. Bcl-XL also increases the mutagenesis rate61 and promotes resistance of tumor cells to chemotherapy or radiotherapy.62,63 As a result, Bcl-XL may increase the survival of infected T cells with consequent accumulation of genetic mutations that may predispose HTLV-I-infected individuals to the development of ATLL. In addition, it is tempting to speculate that the reduced activity of Tax2 on the Bcl-XL promoter may be associated with a lower long-term survival of HTLV-II-infected cells in vivo and, consequently, a reduced probability to develop leukemia.     Footnotes Submitted December 18, 1999; accepted February 24, 2000. Reprints: Christophe Nicot, Basic Research Laboratory, National Cancer Institute, 9000 Rockville Pike, Bldg 41, Rm C303, Bethesda, MD 20892; e-mail: cbeben{at}helix.nih.gov. The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.     References Top Abstract Introduction Materials and methods Results Discussion References 1. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science. 1995;267:1456[Abstract/Free Full Text]. 2. Reed JC. Dysregulation of apoptosis in cancer. Cancer J Sci Am. 1998;4:S8. 3. Reed JC. Mechanisms of apoptosis avoidance in cancer. Curr Opin Oncol. 1999;11:68[Medline] [Order article via Infotrieve]. 4. Chao DT, Korsmeyer SJ. Bcl2 family: regulators of cell death. Annu Rev Immunol. 1998;16:395[Medline] [Order article via Infotrieve]. 5. Reed JC. Bcl-2 family proteins. Oncogene. 1998;17:3225[Medline] [Order article via Infotrieve]. 6. Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science. 1998;281:1322[Abstract/Free Full Text]. 7. Korsmeyer SJ. Bcl2 gene family and the regulation of programmed cell death. Cancer Res. 1999;59(suppl 7):1693s. 8. Kluck RM, Bossy-Wetzel E, Green DR, Newmeyer DD. The release of cytochrome c from mitochondria: a primary site for Bcl2 regulation of apoptosis. Science. 1997;275:1132[Abstract/Free Full Text]. 9. Steller H. Mechanisms and genes of cellular suicide. Science. 1995;267:1445[Abstract/Free Full Text]. 10. Yang E, Korsmeyer SJ. Molecular thanatopsis: a discourse on the Bcl2 family and cell death. Blood. 1996;88:386[Free Full Text]. 11. Cheng EH, Levine B, Boise LH, Thompson CB, Hardwick JM. Bax-independent inhibition of apoptosis by Bcl-XL. Nature. 1996;379:554[Medline] [Order article via Infotrieve]. 12. Knudson CM, Korsmeyer SJ. Bcl2 and Bax function independently to regulate cell death. Nat Genet. 1997;16:358[Medline] [Order article via Infotrieve]. 13. Zha H, Reed JC. Heterodimerization-independent functions of cell death regulatory proteins Bax and Bcl2 in yeast and mammalian cells. J Biol Chem. 1997;272:31482[Abstract/Free Full Text]. 14. Meinl E, Fickenscher H, Thome M, Tschopp J, Fleckenstein B. Anti-apoptotic strategies of lymphotropic viruses. Immunology Today. 1998;19:474[Medline] [Order article via Infotrieve]. 15. Franchini G. Molecular mechanisms of human T-cell leukemia/lymphotropic virus type I infection. Blood. 1995;86:3619[Free Full Text]. 16. Akagi T, Ono H, Shimotohno K. Characterization of T cells immortalized by Tax1 of human T-cell leukemia virus type 1. Blood. 1995;86:4243[Abstract/Free Full Text]. 17. Yamaoka S, Inoue H, Sakurai M, et al. Constitutive activation of NF-kappa B is essential for transformation of rat fibroblasts by the human T-cell leukemia virus type I Tax protein. EMBO J. 1996;15:873[Medline] [Order article via Infotrieve]. 18. Akagi T, Ono H, Tsuchida N, Shimotohno K. Aberrant expression and function of p53 in T-cells immortalized by HTLV-I Tax1. FEBS Lett. 1997;406:263[Medline] [Order article via Infotrieve]. 19. Suzuki T, Kitao S, Matsushime H, Yoshida M. HTLV-1 Tax protein interacts with cyclin-dependent kinase inhibitor p16INK4A and counteracts its inhibitory activity towards CDK4. EMBO J. 1996;15:1607[Medline] [Order article via Infotrieve]. 20. Suzuki T, Narita T, Uchida-Toita M, Yoshida M. Down-regulation of the INK4 family of cyclin-dependent kinase inhibitors by tax protein of HTLV-1 through two distinct mechanisms. Virology. 1999;259:384[Medline] [Order article via Infotrieve]. 21. Ceresto A, Diella F, Mulloy JC, et al. p53 functional impairment and high p21 waf1/cip expression in human T-cell lymphotropic/leukemia virus type I-transformed T cells. Blood. 1996;88:1551[Abstract/Free Full Text]. 22. Jin DY, Spencer F, Jeang KT. Human T cell leukemia virus type 1 oncoprotein Tax targets the human mitotic checkpoint protein MAD1. Cell. 1998;93:81[Medline] [Order article via Infotrieve]. 23. Jeang KT, Widen SG, Semmes OJ, Wilson SH. HTLV-I trans-activator protein, tax, is a trans-repressor of the human beta-polymerase gene. Science. 1990;247:1082[Abstract/Free Full Text]. 24. Kao SY, Marriott SJ. Disruption of nucleotide excision repair by the human T-cell leukemia virus type 1 Tax protein. J Virol. 1999;73:4299[Abstract/Free Full Text]. 25. Bazarbachi A, El-Sabban ME, Nasr R, et al. Arsenic trioxide and interferon- synergize to induce cell cycle arrest and apoptosis in human T-cell lymphotropic virus type I-transformed cells. Blood. 1999;93:278[Abstract/Free Full Text]. 26. Chen GQ, Zhu J, Shi XG, et al. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As) in the treatment of acute promyelocytic leukemia: As induces NB4 cell apoptosis with downregulation of Bcl2 expression and modulation of PML-RAR/PML proteins. Blood. 1996;88:1052[Abstract/Free Full Text]. 27. Gill P, Harrington W, Kaplan M, et al. Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alpha and zidovudine. N Engl J Med. 1995;332:1744[Abstract/Free Full Text]. 28. Hermine O, Bouscary D, Gessain A, et al. Treatment of HTLV-I associated adult T-cell leukemia-lymphoma with a combination of zidovudine and alpha interferon. N Engl J Med. 1995;332:1749[Free Full Text]. 29. Smith MR, Greene WC. Identification of HTLV-I tax trans-activator mutants exhibiting novel transcriptional phenotypes. Genes Dev. 1990;4:1875[Abstract/Free Full Text]. 30. Ross TM, Minella AC, Fang ZY, Pettiford SM, Green PL. Mutational analysis of human T-cell leukemia virus type 2 Tax. J Virol. 1997;71:8912[Abstract]. 31. Aillet F, Matsutani H, Elbim C, et al. Human immunodeficiency virus induces a dual regulation of Bcl2, resulting in persistent infection of CD4+ T- or monocytic cell lines. J Virol. 1998;72:9698[Abstract/Free Full Text]. 32. Sevilla L, Aperlo C, Dulic V, et al. The Ets2 transcription factor inhibits apoptosis induced by colony-stimulating factor 1 deprivation of macrophages through a Bcl-XL-dependent mechanism. Mol Cell Biol. 1999;19:2624[Abstract/Free Full Text]. 33. Nicot C, Astier-Gin T, Guillemain B. Activation of Bcl2 expression in human endothelial cells chronically expressing the human T-cell lymphotropic virus type I. Virology. 1997;236:47[Medline] [Order article via Infotrieve]. 34. Cereseto A, Kislyakova T, Washington Parks R, Nicot C, Franchini G. Differential response to genotoxic stress in immortalized or transformed human T-lymphotropic virus type I-infected T-cells. J Gen Virol. 1999;80:1575[Abstract]. 35. Brauweiler A, Garrus JE, Reed JC, Nyborg JK. Repression of bax gene expression by the HTLV-1 Tax protein: implications for suppression of apoptosis in virally infected cells. Virology. 1997;231:135[Medline] [Order article via Infotrieve]. 36. Tsukahara T, Kannagi M, Ohashi T, et al. Induction of Bcl-XL expression by human T-cell leukemia virus type 1 Tax through NF-B in apoptosis-resistant T-cell transfectants with Tax. J Virol. 1999;73:7981[Abstract/Free Full Text]. 37. Brimmell M, Mendolia R, Mangion J, Packham G. Bax frameshift mutations in cell lines derived from human haemopoietic malignancies are associated with resistance to apoptosis and microsatellite instability. Oncogene. 1998;16:1803[Medline] [Order article via Infotrieve]. 38. Lee HH, Dadgostar H, Chen Q, Shu J, Cheng G. NF-kappaB-mediated up-regulation of Bcl-x and Bfl-1/A1 is required for CD40 survival signaling in B lymphocytes. Proc Natl Acad Sci U S A. 1999;96:9136[Abstract/Free Full Text]. 39. Minn AJ, Kettlun CS, Liang H. Bcl-xL regulates apoptosis by heterodimerization-dependent and -independent mechanisms. EMBO J. 1999;18:632[Medline] [Order article via Infotrieve]. 40. Shinoura N, Yoshida Y, Asai A, Kirino T, Hamada H. Relative level of expression of Bax and Bcl-xL determines the cellular fate of apoptosis/necrosis induced by the overexpression of Bax. Oncogene. 1999;18:5703[Medline] [Order article via Infotrieve]. 41. Hogarth LA, Hall AG. Increased Bax expression is associated with an increased risk of relapse in childhood acute lymphocytic leukemia. Blood. 1999;93:2671[Abstract/Free Full Text]. 42. Mori N, Fujii M, Ikeda S, et al. Constitutive activation of NF-kappaB in primary adult T-cell leukemia cells. Blood. 1999;93:2360[Abstract/Free Full Text]. 43. Arima N, Matsushita K, Obata H, et al. NF-kappaB involvement in the activation of primary adult T-cell leukemia cells and its clinical implications. Exp Hematol. 1999;27:1168[Medline] [Order article via Infotrieve]. 44. Kitajima I, Shinohara T, Bilakovics J, Brown DA, Xu X, Nerenberg M. Ablation of transplanted HTLV-I Tax transformed tumors in mice by antisense inhibition of NF-kappaB. Science. 1992;258:1792[Abstract/Free Full Text]. 45. Higgins KA, Perez JR, Coleman TA, et al. Antisense inhibition of the p65 subunit of NF-kappaB blocks tumorigenicity and causes tumor regression. Proc Natl Acad Sci U S A. 1993;90:9901[Abstract/Free Full Text]. 46. Tu Y, Renner S, Xu F, et al. Bcl-x expression in multiple myeloma: possible indicator of chemoresistance. Cancer Res. 1998;58:256[Abstract/Free Full Text]. 47. Xerri L, Parc P, Brousset P, et al. Predominant expression of the long isoform of Bcl-x (Bcl-xL) in human lymphomas. Br J Hematol. 1996;92:900[Medline] [Order article via Infotrieve]. 48. Olopade OI, Adeyanju MO, Safa AR, et al. Overexpression of BCL-x protein in primary breast cancer is associated with high tumor grade and nodal metastases. Cancer J Sci Am. 1997;3:230[Medline] [Order article via Infotrieve]. 49. Maurer CA, Friess H, Buhler SS, et al. Apoptosis inhibiting factor Bcl-xL might be the crucial member of the Bcl2 gene family in colorectal cancer. Dig Dis Sci. 1998;43:2641[Medline] [Order article via Infotrieve]. 50. Liu JR, Fletcher B, Page C, Hu C, Numez G, Baker V. Bcl-xL is expressed in ovarian carcinoma and modulates chemotherapy-induced apoptosis. Gynecol Oncol. 1998;70:398[Medline] [Order article via Infotrieve]. 51. Kondo S, Shinomura Y, Kanayama S, et al. Over-expression of bcl-xL gene in human gastric adenomas and carcinomas. Int J Cancer. 1996;68:727[Medline] [Order article via Infotrieve]. 52. Migone TS, Lin JX, Cereseto A, et al. Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I. Science. 1995;269:79[Abstract/Free Full Text]. 53. Takemoto S, Mulloy JC, Cereseto A, et al. Proliferation of adult T cell leukemia/lymphoma cells is associated with the constitutive activation of JAK/STAT proteins. Proc Natl Acad Sci U S A. 1997;94:13897[Abstract/Free Full Text]. 54. Mulloy JC, Migone TS, Ross TM, et al. Human and simian T-cell leukemia viruses type 2 (HTLV-2 and STLV-2pan-p) transform T-cells independently of Jak/STAT activation. J Virol. 1998;72:4408[Abstract/Free Full Text]. 55. Reed JC, Cuddy M, Haldar S, et al. BCL2-mediated tumorigenicity of a human T-lymphoid cell line: synergy with MYC and inhibition by BCL2 antisense. Proc Natl Acad Sci U S A. 1990;87:3660[Abstract/Free Full Text]. 56. Harris AW, Strasser A, Bath ML, Elefanty AG, Cory S. Lymphomas and plasmacytomas in transgenic mice involving bcl2, myc and v-abl. Curr Top Microbiol Immunol. 1997;224:221[Medline] [Order article via Infotrieve]. 57. Duyao MP, Kessler DJ, Spicer DB, Sonenshein GE. Transactivation of the c-myc gene by HTLV-1 tax is mediated by NFkB. Curr Top Microbiol Immunol. 1992;182:421[Medline] [Order article via Infotrieve]. 58. Saggioro D, D'agostino DM, Chieco-Bianchi L. Analysis of Tax-expressing cell lines generated from HTLV-I tax-transgenic mice: correlation between c-myc overexpression and neoplastic potential. Exp Cell Res. 1999;247:525[Medline] [Order article via Infotrieve]. 59. Pozzatti R, Vogel J, Jay G. The human T-lymphotropic virus type 1 tax gene can cooperate with the ras oncogene to induce neoplastic transformation of cells. Mol Cell Biol. 1990;10:413[Abstract/Free Full Text]. 60. Matsumoto K, Akashi K, Shibata H, Yutsudo M, Hakura A. Single amino acid substitution (58Pro-Ser) in HTLV-I Tax results in loss of ras cooperative focus formation in rat embryo fibroblasts. Virology. 1994;200:813[Medline] [Order article via Infotrieve]. 61. Cherbonnel-Lasserre C, Dosanjh MK. Suppression of apoptosis by over-expression of Bcl2 or Bcl-xL promotes survival and mutagenesis after oxidative damage. Biochimie. 1997;79:613[Medline] [Order article via Infotrieve]. 62. Datta R, Manome Y, Taneja N, et al. Over-expression of Bcl-XL by cytotoxic drug exposure confers resistance to ionizing radiation-induced internucleosomal DNA fragmentation. Cell Growth Differ. 1995;6:363[Abstract]. 63. Simonian PL, Grillot DA, Nunez G. Bcl2 and Bcl-XL can differentially block chemotherapy-induced cell death. Blood. 1997;90:1208[Abstract/Free Full Text]. © 2000 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: K. Silbermann, G. Schneider, and R. Grassmann Stimulation of interleukin-13 expression by human T-cell leukemia virus type 1 oncoprotein Tax via a dually active promoter element responsive to NF-{kappa}B and NFAT J. Gen. Virol., November 1, 2008; 89(11): 2788 - 2798. [Abstract] [Full Text] [PDF] M. Bellon and C. Nicot Central role of PI3K in transcriptional activation of hTERT in HTLV-I-infected cells Blood, October 1, 2008; 112(7): 2946 - 2955. [Abstract] [Full Text] [PDF] M. Baba, M. Okamoto, T. Hamasaki, S. Horai, X. Wang, Y. Ito, Y. Suda, and N. Arima Highly Enhanced Expression of CD70 on Human T-Lymphotropic Virus Type 1-Carrying T-Cell Lines and Adult T-Cell Leukemia Cells J. Virol., April 15, 2008; 82(8): 3843 - 3852. [Abstract] [Full Text] [PDF] P. Banerjee, R. Rochford, J. Antel, G. Canute, S. Wrzesinski, M. Sieburg, and G. Feuer Proinflammatory Cytokine Gene Induction by Human T-Cell Leukemia Virus Type 1 (HTLV-1) and HTLV-2 Tax in Primary Human Glial Cells J. Virol., February 15, 2007; 81(4): 1690 - 1700. [Abstract] [Full Text] [PDF] M. Brown, M. Bellon, and C. Nicot Emodin and DHA potently increase arsenic trioxide interferon-{alpha}-induced cell death of HTLV-I-transformed cells by generation of reactive oxygen species and inhibition of Akt and AP-1 Blood, February 15, 2007; 109(4): 1653 - 1659. [Abstract] [Full Text] [PDF] S. Ghorbel, U. Sinha-Datta, M. Dundr, M. Brown, G. Franchini, and C. Nicot Human T-cell Leukemia Virus Type I p30 Nuclear/Nucleolar Retention Is Mediated through Interactions with RNA and a Constituent of the 60 S Ribosomal Subunit J. Biol. Chem., December 1, 2006; 281(48): 37150 - 37158. [Abstract] [Full Text] [PDF] S. Calattini, S. A. Chevalier, R. Duprez, P. Afonso, A. Froment, A. Gessain, and R. Mahieux Human T-Cell Lymphotropic Virus Type 3: Complete Nucleotide Sequence and Characterization of the Human Tax3 Protein J. Virol., October 1, 2006; 80(19): 9876 - 9888. [Abstract] [Full Text] [PDF] A. Datta, M. Bellon, U. Sinha-Datta, A. Bazarbachi, Y. Lepelletier, D. Canioni, T. A. Waldmann, O. Hermine, and C. Nicot Persistent inhibition of telomerase reprograms adult T-cell leukemia to p53-dependent senescence Blood, August 1, 2006; 108(3): 1021 - 1029. [Abstract] [Full Text] [PDF] T. Okudaira, M. Tomita, J.-N. Uchihara, T. Matsuda, C. Ishikawa, H. Kawakami, M. Masuda, Y. Tanaka, K. Ohshiro, N. Takasu, et al. NIK-333 inhibits growth of human T-cell leukemia virus type I-infected T-cell lines and adult T-cell leukemia cells in association with blockade of nuclear factor-{kappa}B signal pathway. Mol. Cancer Ther., March 1, 2006; 5(3): 704 - 712. [Abstract] [Full Text] [PDF] K. Okamoto, J.-i. Fujisawa, M. Reth, and S. Yonehara Human T-cell leukemia virus type-I oncoprotein Tax inhibits Fas-mediated apoptosis by inducing cellular FLIP through activation of NF-{kappa}B Genes Cells, February 1, 2006; 11(2): 177 - 191. [Abstract] [Full Text] [PDF] M. Z. Dewan, J.-n. Uchihara, K. Terashima, M. Honda, T. Sata, M. Ito, N. Fujii, K. Uozumi, K. Tsukasaki, M. Tomonaga, et al. Efficient intervention of growth and infiltration of primary adult T-cell leukemia cells by an HIV protease inhibitor, ritonavir Blood, January 15, 2006; 107(2): 716 - 724. [Abstract] [Full Text] [PDF] L. Gao, H. Deng, H. Zhao, A. Hirbe, J. Harding, L. Ratner, and K. Weilbaecher HTLV-1 Tax transgenic mice develop spontaneous osteolytic bone metastases prevented by osteoclast inhibition Blood, December 15, 2005; 106(13): 4294 - 4302. [Abstract] [Full Text] [PDF] M. Watanabe, T. Ohsugi, M. Shoda, T. Ishida, S. Aizawa, M. Maruyama-Nagai, A. Utsunomiya, S. Koga, Y. Yamada, S. Kamihira, et al. Dual targeting of transformed and untransformed HTLV-1-infected T cells by DHMEQ, a potent and selective inhibitor of NF-{kappa}B, as a strategy for chemoprevention and therapy of adult T-cell leukemia Blood, October 1, 2005; 106(7): 2462 - 2471. [Abstract] [Full Text] [PDF] U. Sinha-Datta, I. Horikawa, E. Michishita, A. Datta, J. C. Sigler-Nicot, M. Brown, M. Kazanji, J. C. Barrett, and C. Nicot Transcriptional activation of hTERT through the NF-{kappa}B pathway in HTLV-I-transformed cells Blood, October 15, 2004; 104(8): 2523 - 2531. [Abstract] [Full Text] [PDF] M. Sieburg, A. Tripp, J.-W. Ma, and G. Feuer Human T-Cell Leukemia Virus Type 1 (HTLV-1) and HTLV-2 Tax Oncoproteins Modulate Cell Cycle Progression and Apoptosis J. Virol., October 1, 2004; 78(19): 10399 - 10409. [Abstract] [Full Text] [PDF] N. Mori, T. Matsuda, M. Tadano, T. Kinjo, Y. Yamada, K. Tsukasaki, S. Ikeda, Y. Yamasaki, Y. Tanaka, T. Ohta, et al. Apoptosis Induced by the Histone Deacetylase Inhibitor FR901228 in Human T-Cell Leukemia Virus Type 1-Infected T-Cell Lines and Primary Adult T-Cell Leukemia Cells J. Virol., May 1, 2004; 78(9): 4582 - 4590. [Abstract] [Full Text] [PDF] A. Tripp, Y. Liu, M. Sieburg, J. Montalbano, S. Wrzesinski, and G. Feuer Human T-Cell Leukemia Virus Type 1 Tax Oncoprotein Suppression of Multilineage Hematopoiesis of CD34+ Cells In Vitro J. Virol., November 15, 2003; 77(22): 12152 - 12164. [Abstract] [Full Text] [PDF] N. Mori, Y. Yamada, S. Ikeda, Y. Yamasaki, K. Tsukasaki, Y. Tanaka, M. Tomonaga, N. Yamamoto, and M. Fujii Bay 11-7082 inhibits transcription factor NF-kappa B and induces apoptosis of HTLV-I-infected T-cell lines and primary adult T-cell leukemia cells Blood, August 13, 2002; 100(5): 1828 - 1834. [Abstract] [Full Text] [PDF] R. Mahieux, C. Pise-Masison, A. Gessain, John. N. Brady, R. Olivier, E. Perret, T. Misteli, and C. Nicot Arsenic trioxide induces apoptosis in human T-cell leukemia virus type 1- and type 2-infected cells by a caspase-3-dependent mechanism involving Bcl-2 cleavage Blood, December 15, 2001; 98(13): 3762 - 3769. [Abstract] [Full Text] [PDF] C. Nicot, R. Mahieux, C. Pise-Masison, J. Brady, A. Gessain, S. Yamaoka, and G. Franchini Human T-Cell Lymphotropic Virus Type 1 Tax Represses c-Myb-Dependent Transcription through Activation of the NF-{kappa}B Pathway and Modulation of Coactivator Usage Mol. Cell. Biol., November 1, 2001; 21(21): 7391 - 7402. [Abstract] [Full Text] [PDF] T. Ruckes, D. Saul, J. Van Snick, O. Hermine, and R. Grassmann Autocrine antiapoptotic stimulation of cultured adult T-cell leukemia cells by overexpression of the chemokine I-309 Blood, August 15, 2001; 98(4): 1150 - 1159. [Abstract] [Full Text] [PDF] C. Nicot, J. C. Mulloy, M. G. Ferrari, J. M. Johnson, K. Fu, R. Fukumoto, R. Trovato, J. Fullen, W. J. Leonard, and G. Franchini HTLV-1 p12I protein enhances STAT5 activation and decreases the interleukin-2 requirement for proliferation of primary human peripheral blood mononuclear cells Blood, August 1, 2001; 98(3): 823 - 829. [Abstract] [Full Text] [PDF] C. Nicot and R. Harrod Distinct p300-Responsive Mechanisms Promote Caspase-Dependent Apoptosis by Human T-Cell Lymphotropic Virus Type 1 Tax Protein Mol. Cell. Biol., November 15, 2000; 20(22): 8580 - 8589. [Abstract] [Full Text] M. E. El-Sabban, R. Nasr, G. Dbaibo, O. Hermine, N. Abboushi, F. Quignon, J. C. Ameisen, F. Bex, H. de The, and A. Bazarbachi Arsenic-interferon-alpha -triggered apoptosis in HTLV-I transformed cells is associated with Tax down-regulation and reversal of NF-kappa B activation Blood, October 15, 2000; 96(8): 2849 - 2855. [Abstract] [Full Text] [PDF] This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Nicot, C. Articles by Franchini, G. Search for Related Content PubMed PubMed Citation Articles by Nicot, C. Articles by Franchini, G. Related Collections Neoplasia Apoptosis Social Bookmarking                   What's this?

	Copyright © 2000 by American Society of Hematology         Online ISSN: 1528-0020